ICU Medical Incorporated (ICUI) reported quarterly earnings results on Tuesday, May-10-2016. The company said it had a profit of $1.14 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.16. Analysts had a consensus of $0.98. The company posted revenue of $89.80 million in the period, compared to analysts expectations of $88.04 million. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS.
Many Wall Street Analysts have commented on ICU Medical Incorporated. Gabelli & Co Initiated ICU Medical Incorporated on Mar 11, 2016 to “Buy”, Price Target of the shares are set at $128.
ICU Medical Incorporated opened for trading at $101.1 and hit $102.11 on the upside on Friday, eventually ending the session at $101.86, with a gain of 0.20% or 0.2 points. The heightened volatility saw the trading volume jump to 1,38,060 shares. Company has a market cap of $1,642 M.
In a different news, on May 9, 2016, Robert S Swinney (director) sold 1,875 shares at $101.40 per share price. According to the SEC, on Apr 15, 2016, Joseph R Saucedo (director) sold 1,875 shares at $103.22 per share price. On Mar 21, 2016, Steven Riggs (VP Operations) sold 20,000 shares at $100.00 per share price, according to the Form-4 filing with the securities and exchange commission.
ICU Medical Inc. is engaged in the development manufacturing and sales of medical devices used in infusion therapy oncology and critical care applications. The Companys product line includes needlefree connection devices custom infusion sets closed system transfer devices (CSTD) for the handling of hazardous drugs advanced sensor catheters needlefree closed blood sampling systems disposable pressure transducer systems and innovative hemodynamic monitoring systems. The Companys products are used in acute care hospitals and ambulatory clinics in more than 60 countries worldwide. Its products are categorized into three market segments: Infusion Therapy Critical Care and Oncology. Its primary products include MicroClave and MicroClave Clear Anti-Microbial MicroClave Tego needlefree hemodialysis connector Transpac disposable pressure transducers Pulmonary artery thermodilution catheters ChemoLock CSTD and components and Diana hazardous drug compounding system among others.